Literature DB >> 15476948

Urotensin II in the cardiovascular system.

A Mark Richards1, Chris Charles.   

Abstract

Urotensin II is a peptide present, together with its receptor, in the central nervous system and many peripheral tissues (including heart, blood vessels, kidneys and endocrine organs) of many species. The bioactive, mature form contains a cyclic heptapeptide perfectly preserved across species spanning 550 million years of evolution Its biological activity has been explored in cultured cells, in isolated vessels from several species, in the isolated perfused heart and in intact animals and man. Initial demonstration of potent vasoconstriction and cardiac depression by the human isoform in non-human primates has been followed by a series of reports indicating potent but highly variable and generally modest vascular responses dependent on species and vascular region. In man short term cardiovascular responses to administered urotensin II are small or absent. The place of urotensin II in the chronic trophic responses to cardiac and vascular injury and its possible roles as a neurotransmitter and/or regulator of renal and endocrine function remain largely unexplored.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15476948     DOI: 10.1016/j.peptides.2004.04.017

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  8 in total

1.  In vitro siRNA-mediated knockdown of the UT receptor: implications of density on the efficacy of a range of UT ligands.

Authors:  Benjamin D Hunt; Leong L Ng; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-06       Impact factor: 3.000

2.  Palosuran treatment effective as bosentan in the treatment model of pulmonary arterial hypertension.

Authors:  Yavuz Pehlivan; Recep Dokuyucu; Tuncer Demir; Davut Sinan Kaplan; Ibrahim Koc; Mustafa Orkmez; Ibrahim Halil Turkbeyler; Ali Osman Ceribasi; Ediz Tutar; Seyithan Taysi; Bunyamin Kisacik; Ahmet Mesut Onat
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

Review 3.  A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-II effects.

Authors:  Benjamin D Hunt; Leong L Ng; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-04-27       Impact factor: 3.000

4.  Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.

Authors:  Stephen A Douglas; David J Behm; Nambi V Aiyar; Diane Naselsky; Jyoti Disa; David P Brooks; Eliot H Ohlstein; John G Gleason; Henry M Sarau; James J Foley; Peter T Buckley; Dulcie B Schmidt; William E Wixted; Katherine Widdowson; Graham Riley; Jian Jin; Timothy F Gallagher; Stanley J Schmidt; Lance Ridgers; Lisa T Christmann; Richard M Keenan; Steven D Knight; Dashyant Dhanak
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

5.  Urotensin-II receptor stimulation of cardiac L-type Ca2+ channels requires the βγ subunits of Gi/o-protein and phosphatidylinositol 3-kinase-dependent protein kinase C β1 isoform.

Authors:  Yuan Zhang; Jiaoqian Ying; Dongsheng Jiang; Zhigang Chang; Hua Li; Guoqiang Zhang; Shan Gong; Xinghong Jiang; Jin Tao
Journal:  J Biol Chem       Date:  2015-02-12       Impact factor: 5.157

6.  The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.

Authors:  David J Behm; Gerald Stankus; Christopher P A Doe; Robert N Willette; Henry M Sarau; James J Foley; Dulcie B Schmidt; Parvathi Nuthulaganti; James A Fornwald; Robert S Ames; David G Lambert; Girolamo Calo'; Valeria Camarda; Nambi V Aiyar; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

7.  Effect of urotensin II on apolipoprotein B100 and apolipoprotein A-I expression in HepG2 cell line.

Authors:  Abbas Mohammadi; Ahmad Gholamhoseinian Najar; Amirhosein Khoshi
Journal:  Adv Biomed Res       Date:  2014-01-09

8.  Plasma Urotensin II levels in children and adolescents with chronic kidney disease: a single-centre study.

Authors:  Anastasia Garoufi; Styliani Drapanioti; Antonios Marmarinos; Varvara Askiti; Andromachi J Mitsioni; Maria Mila; Georgia Grigoriadou; Dimitrios Georgakopoulos; Constantinos J Stefanidis; Dimitrios Gourgiotis
Journal:  BMC Nephrol       Date:  2017-03-31       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.